Physician profile
David A Vincent
NPI 1003454349
$4,634.18
in general payments reported to CMS, 2019-2025
18 companies · $1,718 in 2025
The $1,718 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $188 · 2022: $169 · 2023: $1,172 · 2024: $1,387 · 2025: $1,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,276.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,101.60 | 2021-2025 | |
| Alkermes, INC. | $508.87 | 2022-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $385.61 | 2023-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $378.71 | 2024-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $368.89 | 2023-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $297.23 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $265.55 | 2024-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $246.73 | 2022-2025 | Rexulti, Abilify Maintena |
| Bausch Health US, LLC | $213.43 | 2021-2025 | Aplenzin |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $204.50 | 2023-2025 | Caplyta |
| Lundbeck LLC | $194.81 | 2023-2025 | Rexulti, Brintellix |
| Teva Pharmaceuticals USA, INC. | $147.63 | 2023-2025 | Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $117.26 | 2025 | Qelbree |
| Corium, LLC | $98.76 | 2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $52.61 | 2025 | Jornay Pm |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $19.43 | 2021 | |
| Owp Pharmaceuticals, INC. | $17.83 | 2023 | Lamotrigine, Subvenite |
| Tempus Ai, INC | $14.73 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Vincent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.